Healthcare
Live Price
Offline$1.70
+6.92% today
1Y Change
-37.28%
Window
Jun 20, 2025 → Jun 15, 2026
Coverage: 248 bars · Jun 20, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shandong Weigao Group Medical Polymer Company Limited (SHWGY) is a Healthcare stock with a market cap of $13.36B and listed on OTC. The stock last traded around $1.70 and down 37.3% across the available one-year price window (Jun 20, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -0.5%, EPS growth of -23.9%, a dividend yield of 7.0%. What stands out right now is revenue -0.5%, EPS -23.9%, free cash flow -19.8% with operating margin 14.1% and ROIC 4.9%. The dividend matters to the case here, with a current yield around 7.0%. Valuation is more restrained than many high-expectation growth names at P/E 8.4 and price/sales 1.0. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SHWGY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHWGY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SHWGY Max Drawdown
-54.42%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SHWGY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$13.2B
-3.4% YoY
FY Net Income
$2.3B
-17.7% YoY
Free Cash Flow
$1.7B
-11.3% YoY
Revenue Growth
-0.5%
EPS Growth
-23.9%
Gross Margin
46.6%
Net Margin
12.1%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 13.0B | 13.1B | 13.2B | 13.6B | 13.2B |
| Gross Profit | 5.9B | 6.6B | 6.6B | 7.3B | 7.4B |
| Operating Income | 1.8B | 2.4B | 2.3B | 2.9B | 2.9B |
| EBITDA | 2.8B | 3.8B | 3.6B | 4.4B | 3.8B |
| Net Income | 1.6B | 2.1B | 2.0B | 2.8B | 2.3B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9.0B | 7.8B | 7.0B | 6.9B | 6.6B |
| Total Assets | 36.1B | 34.8B | 33.7B | 33.2B | 30.4B |
| Total Liabilities | 10.2B | 9.4B | 9.7B | 9.7B | 9.5B |
| Shareholder Equity | 24.1B | 23.8B | 22.4B | 21.7B | 19.3B |
| Total Debt | 6.0B | 4.2B | 4.2B | 4.5B | 4.1B |
| Net Debt | -3.0B | -3.6B | -2.8B | -2.4B | -2.5B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2.7B
-11.2% YoY
Capital Expenditures
996M
+10.9% YoY
Free Cash Flow
1.7B
-11.3% YoY
Key ratios
Gross Margin
46.6%
Operating Margin
14.1%
Net Margin
12.1%
ROE
6.6%
Debt / Equity
0.25x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.